Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
David Martín-RodríguezServicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, 18014 Granada, Spain.ORCID 0009-0004-1969-576X
Juan Francisco Gutiérrez-BautistaServicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, 18014 Granada, Spain.ORCID 0000-0003-1374-0756
Mónica BernalServicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
Antonio Rodriguez-NicolasLaboratorio de Inmunología, Servicio de Hematología, Hospital Regional Universitario Carlos Haya, 29010 Malaga, Spain.
José Ramón VílchezServicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
Ana Marín-SánchezServicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
Antonio Rosales-CastilloServicio de Medicina Interna, Hospital Universitario Virgen de Las Nieves, 18014 Granada, Spain.
Juan SainzGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, 18016 Granada, Spain.ORCID 0000-0002-9355-2423
Antonio José Cabrera-SerranoGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, 18016 Granada, Spain.ORCID 0000-0003-0346-7960
Jorge Ceron-HernandezGenomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, 18016 Granada, Spain.ORCID 0000-0002-0304-221X
Miguel Ángel López-NevotServicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, 18014 Granada, Spain.ORCID 0000-0002-3465-6062
Francisco Ruiz-CabelloServicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, 18014 Granada, Spain.ORCID 0000-0002-2247-3293
Pilar JiménezServicio de Análisis Clínicos e Inmunología, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Natural killer (NK) cells play a key role in the innate immune response against viral infections. Their activity is regulated by a balance of activating and inhibitory signals, which are modulated by interactions with HLA class I molecules, including HLA-E. The
Indexed as
COVID-19HLA-B AntigensAdultAgedFemaleGenotypeHumansKiller Cells, NaturalMaleMiddle AgedSARS-CoV-2Severity of Illness IndexHLA-B AntigensCOVID-19HLA-ENK cells
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.